Cardiovascular effects and safety of (non-aspirin) NSAIDs
The DOI matches its Crossref record; 113 of the 116 references it cites were found in a registry or an index.
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective, widely used analgesics. For the past 2 decades, considerable attention has been focused on their cardiovascular safety. After early studies indicating an association between NSAID use and increased risks of heart failure and elevated blood pressure, subsequent studies found a link between NSAID use and an increased risk of thrombotic events. Selective cyclooxygenase 2 (COX2) inhibitors (also known as coxibs) have been associated with the greatest risk of adverse vascular effects but concern also relates to non-selective NSAIDs, especially those with strong COX2 inhibition such as diclofenac. Although NSAID use is discouraged in patients with cardiovascular disease, pain-relief medication is often required and, in the absence of analgesics that are at least as effective but safer, NSAIDs are frequently prescribed. Furthermore, non-prescription use of NSAIDs, even among people with underlying cardiovascular risks, is largely unsupervised and varies widely between countries. As concern mounts about the disadvantages of alternatives to NSAIDs (such as opioids) for pain management, the use of NSAIDs is likely to rise. Given that the pharmaceutical development pipeline lacks new analgesics, health-care professionals, patients and medicine regulatory authorities are focused on optimizing the safe use of NSAIDs. In this Review, we summarize the current evidence on the cardiovascular safety of NSAIDs and present an approach for their use in the context of holistic pain management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paracetamol remains probably safer than NSAIDs which showed a significant increase in adverse cardiovascular outcomes amongst patients receiving non-aspirin NSAIDs.99”
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Hunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century
Case, A., & Deaton, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518393112 · Cited by 2,759
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Research works printed but not linked: 1
- BioSpace. Galt Pharmaceuticals receives FDA priority review for non-controlled pain management drug, orphengesic forte, an opioid-free alternative for patients. BioSpace https://www.biospace.com/article/releases/galt-pharmaceuticals-receives-fda-priority-review-for-non-controlled-pain-management-drug-orphengesic-forte-an-opioid-free-alternative-for-patients/ (2019).
Cited by
An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
Saha, S., Buttari, B., Panieri, E., Profumo, E., & Saso, L. (2020) · Molecules · doi:10.3390/molecules25225474 · Cited by 1,388
“Nonsteroidal anti-inflammatory drugs (NSAIDs) including traditional non-selective NSAIDS (nsNSAIDs) and cyclo-oxygenase-2 selective NSAIDs (COXIBs), are one of the most common medication for inflammation [219].”
BackgroundBioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Pharmaceutical treatment of osteoarthritis
Richard, M. J., Driban, J. B., & McAlindon, T. E. (2023) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2022.11.005 · Cited by 324
Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder
Usui, N., Kobayashi, H., & Shimada, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065487 · Cited by 237
“NSAIDs work by inhibiting the activity of cyclooxygenase enzymes such as COX‐1 and COX‐2, which are involved in the synthesis of prostaglandins, responsible for inflammation, and thromboxane, responsible for blood clotting [139,140].”
BackgroundBai, R., Yao, C., Zhong, Z., Ge, J., Bai, Z., Ye, X., Xie, T., & Xie, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113165 · Cited by 181
Metadata
- Authors
- Schjerning, A.-M., McGettigan, P., & Gislason, G.
- Affiliations
- Zealand University Hospital (DK)
- Queen Mary University of London (GB)
- University of Copenhagen (DK)
- Corresponding author
- Gislason, Gunnar
- Venue
- Nature Reviews Cardiology
- Published
- 2020-04-22
- Volume
- 17
- Issue
- 9
- Pages
- 574-584
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W3020716837
- Cited by
- 387
- References
- 116
- Citations by year
- 2026: 52 · 2025: 76 · 2024: 82 · 2023: 68 · 2022: 69 · 2021: 31 · 2020: 9
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- nonsteroidal anti-inflammatory drugs, cardiovascular safety, heart failure, blood pressure, thrombotic complications, COX-2 inhibitors, diclofenac, pain management, analgesics, drug safety
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Humans, Middle Aged, Risk, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular effects and safety of (non-aspirin) NSAIDs. https://app.cochat.ai/papers/10.1038/s41569-020-0366-z
- The paper
- Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-020-0366-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.